SCHEMBL4125957

SCHEMBL4125957

NC(=O)N(C(=O)c1ccccc1)C(=O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
TSHR P16473 2/20 0.54
CYP2C19 P33261 2/20 0.54
POLB P06746 1/20 0.54
CYP3A4 P08684 1/20 0.54
PARP1 P09874 1/20 0.54
MAPT P10636 1/20 0.54
RECQL P46063 1/20 0.54
BLM P54132 1/20 0.54
PMP22 Q01453 1/20 0.54
HSD17B10 Q99714 1/20 0.54
ALDH1A1 P00352 3/20 0.46
CES2 O00748 2/20 0.46
CES1 P23141 2/20 0.46
DAO P14920 1/20 0.46
NAPRT Q6XQN6 1/20 0.46
GAA P10253 1/20 0.43
TRPM8 Q7Z2W7 1/20 0.43
ADRA2C P18825 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11589556 0.87 TDP1 (0.46) TDP1L3MBTL1TSHRCYP2C19POLB
SCHEMBL27645357 0.87 TDP1 (0.46) TDP1L3MBTL1TSHRCYP2C19POLB
SCHEMBL9284893 0.85 F7 (0.59) TDP1TSHRCYP3A4ALDH1A1GAA
SCHEMBL1574223 0.85 CES1 (0.55) TDP1L3MBTL1TSHRCYP2C19POLB
SCHEMBL9284891 0.84 KMT2A (0.56) L3MBTL1TSHRMAPTHSD17B10ALDH1A1
SCHEMBL13377799 0.82 AKT1 (0.47) TDP1L3MBTL1TSHRCYP2C19POLB
SCHEMBL28757765 0.82 ALDH1A1 (0.46) TDP1L3MBTL1TSHRCYP2C19POLB
SCHEMBL28939211 0.82 CYP2C19 (0.50) TDP1L3MBTL1TSHRCYP2C19POLB
SCHEMBL6933107 0.82 BLM (0.50) TDP1L3MBTL1TSHRCYP2C19POLB
SCHEMBL6267389 0.82 TSHR (0.50) TDP1L3MBTL1TSHRCYP2C19POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104710491-A Preparation method for (2'R)-2'-deoxy-2'-fluoro-2'-methyluridine NINGBO CHEMGOO PHARMACEUTICAL TECHNOLOGY INNOVATION LTD 2015-06-17 CN claimed
US-6946554-B2 Process for the preparation of 9-deazaguanine derivatives BIOCRYST PHARMACEUTICALS, INC. (US) 2005-09-20 US claimed
US-20040254181-A1 Process for the preparation of 9-deazaguanine derivatives BIOCRYST PHARMACEUTICALS, INC. 2004-12-16 US claimed
CN-122080093-A Compounds effective in treating liver toxicity and fatty liver disease and uses thereof 2026-05-26 CN disclosed
US-20250382514-A1 CURABLE ADHESIVE COMPOSITION COMPRISING MALEIMIDE AND THIOL HENKEL AG & CO KGAA (DE) 2025-12-18 US disclosed
US-12460043-B2 Epoxy resin composition for fiber-reinforced composite material, prepreg, and fiber-reinforced composite material THE YOKOHAMA RUBBER CO., LTD. (JP) 2025-11-04 US disclosed
EP-4282902-B1 RESIN COMPOSITION, CURED PRODUCT, SEALING MATERIAL, ADHESIVE, INSULATING MATERIAL, COATING MATERIAL, PREPREG, MULTILAYERED BODY, AND FIBER-REINFORCED COMPOSITE MATERIAL MITSUBISHI GAS CHEMICAL CO (JP) 2025-07-02 EP disclosed
CN-119365518-A Resin composition, cured product, sealing material, adhesive, insulating material, coating material, prepreg, multilayer body, and fiber-reinforced composite material 三菱瓦斯化学株式会社 2025-01-24 CN disclosed
EP-4392998-A1 ELECTRICALLY CONDUCTIVE ADHESIVE COMPOSITION FOR BONDING SOLAR CELLS Henkel AG & Co. KGaA (DE) 2024-07-03 EP disclosed
US-20240199925-A1 ELECTRICALLY CONDUCTIVE ADHESIVE COMPOSITION FOR BONDING SOLAR CELLS HENKEL AG & CO KGAA (DE) 2024-06-20 US disclosed
US-20240124621-A1 CURABLE COMPOSITION AND USE THEREOF HENKEL AG & CO KGAA (DE) 2024-04-18 US disclosed
US-6946554-B2 Process for the preparation of 9-deazaguanine derivatives BIOCRYST PHARMACEUTICALS, INC. (US) 2005-09-20 US disclosed
US-20040254181-A1 Process for the preparation of 9-deazaguanine derivatives BIOCRYST PHARMACEUTICALS, INC. 2004-12-16 US disclosed
US-6303264-B1 PROFILE OF PATTERN OF QUARTER MICRON ORDER WITHOUT CAUSING FOOTING, WHILE RETAINING HIGH RESOLUTION ABILITY AND HIGH SENSITIVITY WAKO PURE CHEMICAL INDUSTRIES, LTD (JP) 2001-10-16 US disclosed
US-6180250-B1 EPOXY RESIN OBTAINED BY GLYCIDYL ETHERIFYING A CONDENSATION PRODUCT OF A PHENOL AND HYDROXYBENZALDEHYDE; CONDENSATION PRODUCT OF BISPHENOL A AND FORMALDEHYDE; AND A UREA DERIVATIVE. HITACHI CHEMICAL CO., LTD. (JP) 2001-01-30 US disclosed
EP-0970029-A1 PROCESS FOR THE PREPARATION OF 9-DEAZAGUANINE DERIVATIVES BIOCRYST PHARMACEUTICALS INC. (US) 2000-01-12 EP disclosed
EP-0875787-A1 Method for reducing the substrate dependence of resist Wako Pure Chemical Industries, Ltd. (JP) 1998-11-04 EP disclosed
EP-0870805-A2 Epoxy composition for printed circuit boards Hitachi Chemical Co., Ltd. (JP) 1998-10-14 EP disclosed
WO-1997021653-A1 PROCESS FOR THE PREPARATION OF 9-DEAZAGUANINE DERIVATIVES BIOCRYST PHARMACEUTICALS, INC. (US) 1997-06-19 WO disclosed
US-5308743-A USED IN THE MANUFACTURE OF SEMICONDUCTORS AND ELECTRONIC DEVICES FUJI PHOTO FILM CO., LTD. (JP) 1994-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254181-A1 Process for the preparation of 9-deazaguanine derivatives ALKBH3, ALKBH2, ALKBH1 TDP1 646/4885L3MBTL1 4370/4885TSHR 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.